Restless legs syndrome treatment
Its recognition and treatment are essential. However, screening methods present limitations and should be improved. Moreover, available RLS treatment options albeit providing sustained relief to many patients are limited in number. Additionally, the development of augmentation with dopamine agonists represents a major treatment problem. A better understanding of RLS pathomechanisms can bring to light novel treatment possibilities. With emerging new avenues of research in pharmacology, imaging, genetics, and animal models of RLS, this is an interesting and constantly growing field of research 1).
The magnitude of the placebo response in RLS is above the threshold of Minimal clinically important difference, and the frequency of adverse events is also considerable. These results are relevant to inform the design and interpretation of future clinical trials 2).
In patients who responded to treatment, ferric carboxymaltose may require more time to stabilize restless legs syndrome than previously assumed 3).